川芎嗪联合长春西汀治疗急性脑梗死的疗效及不良反应

Efficacy and adverse effects of ligustrazine combined with vinpocetine in the treatment of acute cerebral infarction

目的观察川芎嗪联合长春西汀治疗急性脑梗死的临床效果及安全性。方法抽取2019年3月-2020年1月山东省淄博市淄川区医院神经内科收治的急性脑梗死患者86例,通过抽签法随机分为观察组和对照组,每组43例。对照组行长春西汀治疗,观察组行川芎嗪联合长春西汀治疗,比较2组临床疗效、治疗前后神经功能缺损量表(NIHSS)评分、Barthel指数评分、血液流变学指标及不良反应。结果观察组临床治疗总有效率为95.35%,高于对照组的76.74%,差异有统计学意义(χ^(2)=4.746,P<0.05)。治疗后,2组NIHSS评分及血液流变学指标均低于治疗前,Barthel指数评分均高于治疗前,且观察组NIHSS评分及血液流变学指标均低于对照组,Barthel指数评分均高于对照组,差异均有统计学意义(P<0.01)。观察组不良反应总发生率为6.98%,低于对照组的27.91%,差异有统计学意义(χ^(2)=5.168,P<0.05)。结论川芎嗪联合长春西汀治疗急性脑梗死的临床效果较好,可有效改善患者神经功能及日常生活能力,调节患者血液流变学指标,且不良反应发生率低,可用于临床推广。

Objective To observe the clinical effect and safety of ligustrazine combined with vinpocetine in the treatment of acute cerebral infarction.Methods A total of 86 patients with acute cerebral infarction admitted to Zichuan District Hospital of Zibo City from March 2019 to January 2020 were selected and randomly divided into observation group and control group by drawing lots,with 43 patients in each group.The control group was treated with vinpocetine,and the observation group was treated with ligustrazine combined with vinpocetine.The clinical efficacy,NIHSS scores,Barthel index scores,hemorheological indexes and adverse reactions were compared between the two groups before and after treatment.Results The total effective rate of clinical treatment in the observation group was 95.35%,which was higher than 76.74%in the control group,the difference was statistically significant(χ^(2)=4.746,P<0.05).After treatment,the NIHSS scores and hemorheological indexes of the two groups were lower than before treatment,and the Barthel index scores were higher than before treatment.The NIHSS score and hemorheological indexes of the observation group were lower than those of the control group,and the Barthel index scores were higher in the control group,the differences were statistically significant(P<0.01).The total incidence of adverse reactions in the observation group was 6.98%,which was lower than 27.91%in the control group,and the difference was statistically significant(χ^(2)=5.168,P<0.05).Conclusion Ligustrazine combined with vinpocetine has a good clinical effect in the treatment of acute cerebral infarction.It can effectively improve the patient's neurological function and ability of daily living,adjust the patient's hemorrheological indicators,and has a low incidence of adverse reactions.It can be used for clinical promotion.